GTS Securities LLC Has $351,000 Position in Edwards Lifesciences Co. (NYSE:EW)

GTS Securities LLC trimmed its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 73.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,743 shares of the medical research company's stock after selling 13,303 shares during the quarter. GTS Securities LLC's holdings in Edwards Lifesciences were worth $351,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in EW. Vanguard Group Inc. lifted its holdings in Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after buying an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Edwards Lifesciences by 5.3% in the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock valued at $2,458,601,000 after buying an additional 1,678,154 shares during the period. Geode Capital Management LLC increased its stake in shares of Edwards Lifesciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock valued at $1,007,520,000 after buying an additional 126,194 shares during the period. Fisher Asset Management LLC raised its position in shares of Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock worth $723,664,000 after acquiring an additional 696,965 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $610,895,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Down 0.2%

Shares of Edwards Lifesciences stock traded down $0.19 during trading hours on Monday, hitting $78.03. The company's stock had a trading volume of 3,374,673 shares, compared to its average volume of 5,189,528. The company has a market capitalization of $45.77 billion, a PE ratio of 11.20, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a 50 day moving average of $73.49 and a 200 day moving average of $72.57. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Edwards Lifesciences's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.66 EPS. Analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 400 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.51, for a total value of $428,459.64. Following the transaction, the chief executive officer now owns 59,083 shares of the company's stock, valued at approximately $4,106,859.33. The trade was a 9.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 59,012 shares of company stock valued at $4,224,717 over the last quarter. Corporate insiders own 1.29% of the company's stock.

Analyst Ratings Changes

EW has been the subject of a number of research reports. Royal Bank of Canada reiterated an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Piper Sandler raised their target price on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research note on Tuesday, May 13th. Robert W. Baird boosted their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. Truist Financial cut their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Finally, Barclays raised their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.